Clinical Study
The Presence of Anti-HLA Antibodies before and after Allogeneic Hematopoietic Stem Cells Transplantation from HLA-Mismatched Unrelated Donors
Table 1
Patients characteristics (
).
| | Median age (range) | | | Recipient | 37 (13–57) years | | Donor | 36 (19–55) years | Mean time from diagnosis to allo-HSCT
(range) | 0.75 (0.63–10.3) years |
| | | Number (%) |
| | Sex | | | Donor | | | Male | 19 (63.3%) | | Female | 11 (36.7%) | | Recipient | | | Male | 16 (53.3%) | | Female | 14 (46.7%) | | Sex matching | | | Male donor, male recipient | 10 (33.3%) | | Female donor, female recipient | 5 (16.6%) | | Male donor female recipient | 9 (30%) | | Female donor, male recipient | 6 (20%) | | HLA- mismatch | | | Antigen A | 4 (13.3%) | | Antigen C | 12 (40%) | | Antigen DQ | 2 (6.6%) | | Allele A | 2 (6.6%) | | Allele B | 5 (16.6%) | | Allele DQ | 3 (10%) | | Antigen B + Antigen C | 1 (3.3%) | | Antigen A + Allele B | 1 (3.3%) | | Primary indication for allo-HSCT | | | Acute lymphoblastic leukemia (ALL) | 6 (20%) | | Acute myeloid leukemia (AML) | 15 (20%) | | Chronic myeloid leukemia (CML) | 5 (16.6%) | | Chronic lymphocytic leukemia (CLL) | 1 (3.3) | | Severe aplastic anemia (SAA) | 2 (6.6%) | | Paroxysmal nocturnal hemoglobinuria (PNH) | 1 (3.35) | | Preparative regimen | | | Cyclophosphamide | 1 (3.3%) | | TBI + Cyclophosphamide | 6 (20%) | | TBI + Fludarabine | 1 (3.3%) | | Treosulfan + Fludarabine | 6 (20%) | | Busulfan + Cyclophosphamide | 12 (40%) | | Busulfan + Fludarabine | 1 (3.3%) | | Treosulfan + Cyclophosphamide | 1 (3.3%) | | Busulfan + Cyclophosphamide + Gemtuzumab Ozogamycin | 1 (3.3%) | | Rituximab + Alemtuzumab + Melphalan | 1 (3.3%) | | Immunosuppressive treatment | | | Glycocorticoid | 27 (90%) | | Cyclosporine | 30 (100%) | | Mycophenolate mofetil | 7 (23%) | | Tacrolimus | 1 (3.3%) | | Source of cells | | | Bone marrow | 9 (30%) | | Peripheral blood | 21 (70%) |
|
|
